Use of Emerging Models for Developmental Toxicity Testing - Zebrafish: Methods for Assessing Drug Safety and Toxicity - page 36

Table 3.1 ( Continued )

Zebrafish Mammalian models

LC 50 /log
LC 50 (mg/L)

Compound

Target organs LD 50 /log LD 50 (mg/kg) Target organs

Atenolol 532/2.73 Heart 2000/3.3 (mouse, oral), 3000/3.48

(rat, oral), 98.7/1.99 (mouse,
i.v.), 59/1.77 (rat, i.v.)

Developmental, cardiac

Metoprolol tartrate salt 411/2.61 Heart 5500/3.74 (rat, oral), 219/2.34

(rat, i.p.), 90/1.95 (rat, i.v.),
1500/3.18 (mouse, oral)

Labetalol HCl 65.7/1.82 Heart 2114/3.33 (rat, oral), 107/2.03

(rat, i.p.), 53/1.72 (rat, i.v.),
1450/3.16 (mouse, oral),
114/2.06 (mouse, i.p.),
47/1.67 (mouse, i.v.)

Timolol 866/2.94 Heart 1190/3.07 (mouse, oral),

900/2.95 (rat, oral)

Propranolol 59.2/1.77 Heart, liver 565/2.75 (mouse, p.o.) No obvious toxicity

Glipzide 17.8/1.25 GI, liver 1200/3.08 (rat, i.p.) Endocrine

Troglitazone 0.80/0.1 Liver, gastrointestinal Unknown Liver, gastrointestinal

Glyburide

> 123.5/2.09

Liver, gastrointestinal 20/1.3 (rat, oral) Pancreas, gastrointestinal

Acetazolamide

> 444/2.65

Gastrointestinal, liver 2750/3.43 (rat, i.p.), 4500/3.65

(mouse, oral)

Kidneys, eyes

Amiloride

> 532/2.73

Liver, heart 85/1.92 (oral, rat), 56/1.75

(mouse, oral)

Hyperkalemia, kidney, heart

Probenecid 14.3/1.16 Liver 1600/3.2 (rat, oral), 1666/3.22

(mouse, oral), 1000/3 (mouse,
i.p.), 458/2.66 (moue, i.v.)

Liver, kidney